New drug shows promise for tough head and neck cancers
NCT ID NCT05271604
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called ozuriftamab vedotin in 42 people with head and neck cancer that returned or spread. The goal was to see if the drug could shrink tumors and to check for side effects. Participants received the drug alone or with other treatments, and researchers measured how many responded and how long the benefit lasted.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Christiana Care Helen Graham Cancer Center
Newark, Delaware, 19713, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40202, United States
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Washington University Medical Siteman Cancer Center
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tailored nutrition boost recovery from head and neck surgery?
- Can less radiation be safer for throat cancer?
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug boost the power of chemoradiation against head and neck cancer?
- Tissue analysis may guide personalized cancer therapy
- Exercise after cancer therapy: a new way to gauge prognosis?